Loading stock data…
$0.40-0.03 (-7.14%)
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States.
Bone Biologics Corporation in the Healthcare sector is trading at $0.40 with a market capitalization of $1M. Wall Street consensus targets $12.20 (1 analysts), implying a +2941.6% move over the next 12 months. The stock is currently near its 52-week low of $0.40, remaining 64.5% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 24 is oversold, raising the odds of a near-term bounce. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | — | — | — | $0 |
| Operating Income | -$808,106↓ | -$805,054↓ | -$733,105↓ | -$715,274↑ | -$748,075 |
| Net Income | -$773,702↓ | -$765,988↓ | -$684,643↓ | -$666,737↑ | -$740,519 |
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which ...